Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Moodys
Dow
Baxter
McKesson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 210913

See Plans and Pricing

« Back to Dashboard

NDA 210913 describes CEQUA, which is a drug marketed by Sun Pharma Global and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the CEQUA profile page.

The generic ingredient in CEQUA is cyclosporine. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
Summary for 210913
Tradename:CEQUA
Applicant:Sun Pharma Global
Ingredient:cyclosporine
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 210913
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913 NDA Sun Pharmaceutical Industries, Inc. 47335-506 47335-506-96 6 POUCH in 1 BOX (47335-506-96) > 10 VIAL, SINGLE-DOSE in 1 POUCH > .25 mL in 1 VIAL, SINGLE-DOSE
CEQUA cyclosporine SOLUTION;OPHTHALMIC 210913 NDA Sun Pharmaceutical Industries, Inc. 47335-507 47335-507-97 1 POUCH in 1 BOX (47335-507-97) > 10 VIAL, SINGLE-DOSE in 1 POUCH > .25 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;OPHTHALMICStrength0.09%
Approval Date:Aug 14, 2018TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Aug 23, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
Patent:  Start TrialPatent Expiration:Aug 23, 2033Product Flag?YSubstance Flag?Delist Request?
Patented Use:INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Mallinckrodt
Colorcon
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.